Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Trial Profile

Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 05 Dec 2017 According to a Mitsubishi Tanabe Pharma America media release, post-hoc study results will be presented at the 28th International Symposium on ALS/MND in Boston.
    • 05 Dec 2017 According to a Mitsubishi Tanabe Pharma America media release, company announced that the data from this study will be presented at the 28th International Symposium on ALS/MND in Boston.
    • 01 Jul 2017 Results of post-hoc analysis assessing efficacy and safety, published in the Lancet Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top